169 related articles for article (PubMed ID: 31147200)
1. Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics.
Cazzola M; Calzetta L; Page C; Rogliani P; Matera MG
Trends Pharmacol Sci; 2019 Jul; 40(7):452-463. PubMed ID: 31147200
[TBL] [Abstract][Full Text] [Related]
2. Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD.
Cazzola M; Page CP; Wedzicha JA; Celli BR; Anzueto A; Matera MG
Respir Res; 2023 Jul; 24(1):194. PubMed ID: 37517999
[TBL] [Abstract][Full Text] [Related]
3. Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent.
Cazzola M; Page C; Rogliani P; Calzetta L; Matera MG
Drugs; 2020 Nov; 80(17):1799-1809. PubMed ID: 33025535
[TBL] [Abstract][Full Text] [Related]
4. Erdosteine: its relevance in COPD treatment.
Moretti M
Expert Opin Drug Metab Toxicol; 2009 Mar; 5(3):333-43. PubMed ID: 19331595
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial.
Dal Negro RW; Visconti M; Turco P
Pulm Pharmacol Ther; 2015 Aug; 33():47-51. PubMed ID: 26116425
[TBL] [Abstract][Full Text] [Related]
6. Use of mucolytics in COPD: A Delphi consensus study.
Papi A; Avdeev S; Calverley PMA; Cordeiro CR; Jesenak M; Koblížek V; Petkova D; Rogliani P; Tarraf H; Tzanakis N; Ulmeanu R; Uzaslan E; Adir Y
Respir Med; 2020 Dec; 175():106190. PubMed ID: 33217537
[TBL] [Abstract][Full Text] [Related]
7. Erdosteine reduces the exercise-induced oxidative stress in patients with severe COPD: Results of a placebo-controlled trial.
Dal Negro RW; Visconti M
Pulm Pharmacol Ther; 2016 Dec; 41():48-51. PubMed ID: 27651323
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data.
Cazzola M; Floriani I; Page CP
Pulm Pharmacol Ther; 2010 Apr; 23(2):135-44. PubMed ID: 19854285
[TBL] [Abstract][Full Text] [Related]
9. Erdosteine: antitussive and anti-inflammatory effects.
Dal Negro RW
Lung; 2008; 186 Suppl 1():S70-3. PubMed ID: 18185958
[TBL] [Abstract][Full Text] [Related]
10. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis.
Cazzola M; Rogliani P; Calzetta L; Hanania NA; Matera MG
COPD; 2017 Oct; 14(5):552-563. PubMed ID: 28753070
[TBL] [Abstract][Full Text] [Related]
11. Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD.
Dal Negro RW; Visconti M; Micheletto C; Tognella S
Pulm Pharmacol Ther; 2008; 21(2):304-8. PubMed ID: 17889580
[TBL] [Abstract][Full Text] [Related]
12. Effects of erdosteine and its metabolites on bacterial adhesiveness.
Braga PC; Dal Sasso M; Sala MT; Gianelle V
Arzneimittelforschung; 1999 Apr; 49(4):344-50. PubMed ID: 10337454
[TBL] [Abstract][Full Text] [Related]
13. Bacterial adhesiveness: effects of the SH metabolite of erdosteine (mucoactive drug) plus clarithromycin versus clarithromycin alone.
Braga PC; Zuccotti T; Dal Sasso M
Chemotherapy; 2001; 47(3):208-14. PubMed ID: 11306790
[TBL] [Abstract][Full Text] [Related]
14. [Mucolytics in acute and chronic respiratory tract disorders. II. Uses for treatment and antioxidant properties].
Kupczyk M; Kuna P
Pol Merkur Lekarski; 2002 Mar; 12(69):248-52. PubMed ID: 12053601
[TBL] [Abstract][Full Text] [Related]
15. [Bronchial expectorants : pharmacology of bronchial mucomodifiers].
Polu JM; Puchelle E; Sadoul P
Sem Hop; 1984 Feb; 60(9):643-58. PubMed ID: 6324374
[TBL] [Abstract][Full Text] [Related]
16. Antioxidants and mucolytics in COPD management: when (if ever) and in whom?
Hillas G; Nikolakopoulou S; Hussain S; Vassilakopoulos T
Curr Drug Targets; 2013 Feb; 14(2):225-34. PubMed ID: 23256719
[TBL] [Abstract][Full Text] [Related]
17. Erdosteine.
Dechant KL; Noble S
Drugs; 1996 Dec; 52(6):875-81; discussion 882. PubMed ID: 8957158
[TBL] [Abstract][Full Text] [Related]
18. Erdosteine for COPD exacerbations.
Drug Ther Bull; 2008 Oct; 46(10):79-80. PubMed ID: 18832259
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
Rogliani P; Matera MG; Page C; Puxeddu E; Cazzola M; Calzetta L
Respir Res; 2019 May; 20(1):104. PubMed ID: 31133026
[TBL] [Abstract][Full Text] [Related]
20. Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis.
Ricevuti G; Mazzone A; Uccelli E; Gazzani G; Fregnan GB
Thorax; 1988 Aug; 43(8):585-90. PubMed ID: 3051508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
